articleMMWR Morbidity and Mortality Weekly ReportAug 24, 2023DIAMOND OA

Use of Nirsevimab for the Prevention of Respiratory Syncytial Virus Disease Among Infants and Young Children: Recommendations of the Advisory Committee on Immunization Practices — United States, 2023

JMJefferson M. JonesKEKatherine E. Fleming-DutraMMMila M. PrillLELauren E. RoperOBOliver Brooks
PubMed
Indexed incrossrefpubmed

Abstract

Respiratory syncytial virus (RSV) is the leading cause of hospitalization among U.S. infants. In July 2023, the Food and Drug Administration approved nirsevimab, a long-acting monoclonal antibody, for passive immunization to prevent RSV-associated lower respiratory tract infection among infants and young children. Since October 2021, the Advisory Committee on Immunization Practices (ACIP) Maternal and Pediatric RSV Work Group has reviewed evidence on the safety and efficacy of nirsevimab among infants and young children. On August 3, 2023, ACIP recommended nirsevimab for all infants aged

Citation impact

328
total citations
FWCI
67.40
Percentile
100%
References
21
Citations per year

Authors

11

Topics & keywords

Topics
Keywords
  • Medicine
  • Advisory committee
  • Palivizumab
  • Pediatrics
  • Immunization
  • Disease
  • Respiratory tract infections
  • Lower respiratory tract infection
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.

Funding